News and Announcements
Prescient Therapeutics Secures $7.0M Capital Raising
- Published May 18, 2016 4:26PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
18th May 2016, ASX Announcement
- $7.0 M institutional placement
- Rights issue on same terms to raise up to a further $3.4 M
Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company, is pleased to advise the successful completion of of an institutional placement to raise $7.0 million.
The placement, largely to life-science focused Australian institutional investors, has been undertaken which will involve the issue of approximately 77.7 million shares at 9.0 cents per share with 1 attaching option for every 2 shares subscribed (exercisable at 18 cents; expiring 30 June 2018). The placement will be undertaken in two tranches. The first tranche of approximately 19.4 million shares will be unconditional, with shareholders to approve the second tranche (of approximately 58.3 million) and all attaching options.
To view the full announcement, please click on the button below.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
